CL2012000708A1 - Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades. - Google Patents

Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.

Info

Publication number
CL2012000708A1
CL2012000708A1 CL2012000708A CL2012000708A CL2012000708A1 CL 2012000708 A1 CL2012000708 A1 CL 2012000708A1 CL 2012000708 A CL2012000708 A CL 2012000708A CL 2012000708 A CL2012000708 A CL 2012000708A CL 2012000708 A1 CL2012000708 A1 CL 2012000708A1
Authority
CL
Chile
Prior art keywords
compounds
imidazopyrimidine
imidazopyridine
schizophrenia
alzheimer
Prior art date
Application number
CL2012000708A
Other languages
English (en)
Inventor
Sanchez Ruben Alvarez
Daniela Alberati
Zbinden Katrin Groebke
Markus Rudolph
Bernd Kuhn
Konrad Bleicher
Alexander Flohr
Matthias Koerner
Jens-Uwe Peters
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2012000708A1 publication Critical patent/CL2012000708A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPUESTOS DERIVADOS DE IMIDAZOPIRIDINA O IMIDAZOPIRIMIDINA DE FORMULA (I): EN LOS QUE R1 , R2, R3, R4, R5 Y A SON COMO SE HA DEFINIDO EN LA MEMORIA DESCRIPTIVA Y PLIEGO DE REIVINDICACIONES, ASÍ COMO SALES FISIOLÓGICAMENTE ACEPTABLES DE LOS MISMOS, COMPUESTOS QUE INHIBEN PDE10A, PROCEDIMIENTO DE PREPARACIÓN, COMPOSICIONES FARMACÉUTICAS, Y SU USO PARA EL TRATAMIENTO TERAPÉUTICO Y/O PREVENTIVO DE TRASTORNOS PSICÓTICOS, ESQUIZOFRENIA, ENFERMEDAD DE ALZHEIMER, TUMORES SÓLIDOS, ENTRE OTRAS ENFERMEDADES.<br />  
CL2012000708A 2009-09-24 2012-03-22 Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades. CL2012000708A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09171253 2009-09-24

Publications (1)

Publication Number Publication Date
CL2012000708A1 true CL2012000708A1 (es) 2012-09-07

Family

ID=43416552

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000708A CL2012000708A1 (es) 2009-09-24 2012-03-22 Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.

Country Status (23)

Country Link
US (2) US8017604B2 (es)
EP (1) EP2480546B1 (es)
JP (1) JP5629322B2 (es)
KR (1) KR101426624B1 (es)
CN (1) CN102548991B (es)
AR (1) AR078437A1 (es)
BR (1) BR112012006531A2 (es)
CA (1) CA2770087C (es)
CL (1) CL2012000708A1 (es)
CY (1) CY1116120T1 (es)
DK (1) DK2480546T3 (es)
ES (1) ES2530884T3 (es)
HR (1) HRP20150345T1 (es)
IL (1) IL218032A (es)
MX (1) MX2012003469A (es)
PE (1) PE20121438A1 (es)
PH (1) PH12012500355A1 (es)
PL (1) PL2480546T3 (es)
PT (1) PT2480546E (es)
RU (1) RU2502737C2 (es)
SI (1) SI2480546T1 (es)
TW (1) TWI402268B (es)
WO (1) WO2011036127A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470820B2 (en) * 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
WO2012105594A1 (ja) * 2011-02-01 2012-08-09 協和発酵キリン株式会社 縮環複素環誘導体
MX2013009575A (es) 2011-02-18 2014-10-14 Exonhit Therapeutics Sa Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a).
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
EP2574607A1 (en) * 2011-09-06 2013-04-03 F. Hoffmann-La Roche AG PDE10 modulators
CA2846758C (en) * 2011-09-19 2017-09-12 F. Hoffmann-La Roche Ag Triazolopyridine compounds as pde10a inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
BR112015017674A2 (pt) * 2013-01-31 2017-07-11 Hoffmann La Roche compostos rádio marcados
HUE043059T2 (hu) 2013-02-27 2019-07-29 Mochida Pharm Co Ltd Új pirazolszármazék
JP6212628B2 (ja) 2013-04-29 2017-10-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ２−フェニル又は２−ヘタリールイミダゾール［１，２−ａ］ピリジン誘導体
JP2016520047A (ja) * 2013-04-30 2016-07-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピラゾールアミドのＰｄ触媒カップリング
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
WO2015044095A1 (en) * 2013-09-26 2015-04-02 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyridin-7-amines as imaging tools
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
EP3872080B1 (en) 2016-09-02 2023-08-16 Cyclerion Therapeutics, Inc. Fused bicyclic sgc stimulators
CN113698406A (zh) * 2021-08-30 2021-11-26 成都药明康德新药开发有限公司 6-甲基吡唑并[1,5-a]嘧啶-3-胺的合成方法
AR134414A1 (es) * 2023-11-21 2026-01-14 Novartis Ag Imidazoarenos sustituidos y métodos para su uso

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2264403C2 (ru) * 1999-11-10 2005-11-20 Орто-Макнейл Фармасьютикал, Инк. Замещенные 2-арил-3-(гетероарил) имидазо [1,2-а] пиримидины, содержащие их фармацевтические композиции и связанные с ними способы
SE0102808D0 (sv) * 2001-08-22 2001-08-22 Astrazeneca Ab New compounds
DK1557411T3 (da) * 2002-07-12 2012-11-05 Astellas Pharma Inc N-phenyl-(2r,5s)-dimethylpiperazin-derivat
JP4589122B2 (ja) * 2002-12-03 2010-12-01 杏林製薬株式会社 ホスホジエステラーゼ１０ａ阻害剤
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
CN1950372A (zh) * 2004-05-10 2007-04-18 万有制药株式会社 咪唑并吡啶化合物
US7998974B2 (en) * 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
AU2007207053B2 (en) 2006-01-17 2012-05-24 F. Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors
WO2007098169A1 (en) 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
PH12012500355A1 (en) 2019-11-29
IL218032A (en) 2014-06-30
DK2480546T3 (en) 2015-02-02
BR112012006531A2 (pt) 2016-11-22
EP2480546B1 (en) 2014-12-31
CA2770087C (en) 2014-09-09
TW201116530A (en) 2011-05-16
SI2480546T1 (sl) 2015-03-31
CN102548991B (zh) 2015-03-25
RU2502737C2 (ru) 2013-12-27
CN102548991A (zh) 2012-07-04
TWI402268B (zh) 2013-07-21
CA2770087A1 (en) 2011-03-31
JP2013505911A (ja) 2013-02-21
KR20120068943A (ko) 2012-06-27
US8263584B2 (en) 2012-09-11
AR078437A1 (es) 2011-11-09
PE20121438A1 (es) 2012-10-26
WO2011036127A1 (en) 2011-03-31
AU2010299927A1 (en) 2012-03-15
RU2012113128A (ru) 2013-11-10
US20110294779A1 (en) 2011-12-01
ES2530884T3 (es) 2015-03-06
PL2480546T3 (pl) 2015-05-29
IL218032A0 (en) 2012-04-30
CY1116120T1 (el) 2017-02-08
PT2480546E (pt) 2015-02-09
JP5629322B2 (ja) 2014-11-19
US8017604B2 (en) 2011-09-13
MX2012003469A (es) 2012-04-19
EP2480546A1 (en) 2012-08-01
KR101426624B1 (ko) 2014-08-05
HRP20150345T1 (hr) 2015-05-08
US20110071128A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
UY31405A1 (es) &#34;piperidino-dihidrotienopirimidas sustituidas&#34;
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
ECSP088863A (es) Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia
EA017278B9 (ru) Соединения азаиндазола и способы применения
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
UY32302A (es) Carboxamidas heterobicíclicas como inhibidoras de cinasas
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
ATE557015T1 (de) 3,4-diarylpyrazole als proteinkinaseinhibitoren
CU20090184A7 (es) Compuestos amino-heterocíclicos
NI201100130A (es) Derivados de pirimidin indol para el tratamiento de cáncer.
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
CR10573A (es) Derivados del pirazol como inhibidores del citocromo p450
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
UY31672A1 (es) &#34;agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación&#34;
ECSP11011073A (es) Nuevas lactamas como inhibidores de beta secretasa
ECSP099063A (es) Derivados de purina como agonistas de a2a
CR9722A (es) Derivados de benzilpiperazina y su uso medico
CY1116120T1 (el) Παραγωγα ιμιδαζοπυριδινης ή ιμιδαζοπυριμιδινης ως αναστολεις φωσφοδιεστερασης 10α
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia